SEATTLE, Feb. 27, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a vaccine technologies company specializing in the development of innovative immunotherapeutics and vaccines in the areas of oncology and infectious disease, is pleased to announce that Dr. Glynn Wilson, Chief Executive Officer, will be presenting at the 10th Annual BioPartnering North America (BPN) in Vancouver, BC, Canada, February 26-28, 2012.
Participants and delegates at BPN will have the opportunity to meet with life sciences professionals from over 27 countries to explore business opportunities and strategic partnerships with Big Pharma, Venture Capital, and other emerging Biotech companies. BioPartnering is also focused on building ties with industry leaders in the Pacific Rim to create a unique opportunity for the U.S., Canada, and Europe to meet leading life science companies from Asia.
TapImmune will present at 11:30 on Tuesday Feb 28th in a dedicated presentation room, where biotechnology companies from around the world will introduce their companies, key technologies, products and clinical developments, as well as state their companies' partnering and financing goals.
About TapImmune Inc.
Taplmmune Inc. is a vaccine technologies company specializing in the development of innovative gene based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidates, include vaccines designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently preparing for the commencement of a Phase 1 immunotherapy clinical trial targeting Her2Neu in breast cancer using a patented technology developed at the Mayo clinic. TapImmune has the exclusive Option to license this technology. The Company is also developing TAP-based prophylactic vaccines commercially suitable for the prevention of infectious diseases and as Biodefense agents. As a vaccine component, the gene based TAP technology has the potential to significantly improve the efficacy of both prophylactic and immunotherapeutic vaccines as it addresses a fundamental mechanism for T cell recognition and response. Unlike other vaccine technologies that address only the initiation of immune responses, TAP expression also has the unique ability to enhance the effector function of mature killer T cells. This enhancement of effector function is potentially complementary to any/all vaccine approaches that are designed to enhance cellular responses.
The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.